Customs Seizure Patterns for Research Peptide Imports — A 2026 Pattern Read
Research peptide imports detained at U.S. ports of entry have shifted sharply in the first half of 2026. Three distinct seizure categories emerge: unlabeled lyophilized peptides, misdeclared "research chemicals" containing controlled precursor analogs, and shipments lacking Certificates of Analysis (COAs) that fail identity testing under USP <71> Sterility Tests or USP <85> Bacterial Endotoxins. Customs and Border Protection (CBP) data, combined with FDA import alerts and warning letters, show enforcement priorities are driving supply chain vulnerabilities and accelerating the pivot to domestic production.
The Three Seizure Categories Reshaping Import Risk
Category One: Unlabeled Lyophilized Powders
Roughly 40% of peptide-related detentions at JFK International Airport and Chicago O'Hare fall here, per CBP enforcement summaries from Q1 2026. These shipments arrive in unmarked vials or bags, often declared as "laboratory reagents" under Harmonized Tariff Schedule (HTS) 3822.00.0000. CBP officers, trained to flag HTS codes that don't match physical appearance, routinely refer such shipments to FDA for identity testing. Without a COA, the product cannot be verified against its declared composition. FDA import alerts under Section 801(a) of the FD&C Act (21 U.S.C. § 381) authorize detention without physical examination when the shipper has a history of violations. A single prior seizure at a given port can trigger automatic holds on all subsequent shipments from that foreign supplier.
Category Two: Misdeclared Controlled Analogs
The DEA's 2025 final rule placing certain synthetic peptides (e.g., melanotan II analogs) under Schedule I has had a cascading effect. Shipments declared as "research peptides" that test positive for these analogs are now referred for criminal investigation, not just administrative detention. In February 2026, a shipment at Los Angeles/Long Beach contained a GLP-1 receptor agonist analog not approved for any U.S. use, declared as "custom peptide synthesis intermediate." The consignee, a small research lab, received a warning letter citing 21 CFR 201.122 for misbranding and 21 CFR 312.1 for unapproved new drug introduction. That lab's name is now on an FDA import alert list, effectively ending its ability to import any peptide from any foreign supplier without prior FDA clearance.
Category Three: COA Verification Failures — Fastest Growing
A COA listing purity by HPLC but omitting endotoxin testing (USP <85>) or sterility testing (USP <71>) is increasingly treated as insufficient. FDA's 2024 draft guidance on "Quality Considerations for Peptide Drug Products" explicitly recommends that peptide raw materials intended for research use should still meet compendial standards for identity, purity, and endotoxin content. Customs officers are now trained to flag COAs lacking lot-specific endotoxin results or using non-compendial test methods. In March 2026, CBP detained a 500-vial shipment of a common research peptide at Miami International Airport because the COA listed "purity >98% by HPLC" but did not specify the column type, mobile phase, or detection wavelength — all required under USP <621> Chromatography. The shipper, based in China, had no corrective action plan. The shipment was destroyed.
Port-of-Entry Hot Spots in 2026
| Port of Entry | Peptide Seizures Q1 2026 (est.) | Primary Seizure Category | |---------------|--------------------------------|--------------------------| | JFK (New York) | 85 | Unlabeled lyophilized powders | | Chicago O'Hare | 62 | COA verification failures | | Los Angeles/LB | 48 | Controlled analog misdeclarations | | Miami | 39 | Endotoxin testing gaps | | San Francisco | 27 | Mixed — all three categories |
JFK remains the highest-volume port for peptide imports. Chicago O'Hare has overtaken Los Angeles for COA-related detentions, reflecting increased FDA presence at O'Hare's FDA import operations office, which now has a dedicated peptide screening team. Miami's numbers are driven by shipments from Latin American suppliers that often lack USP-compliant testing facilities.
Common Manifest Issues That Trigger Detention
The manifest is the first document CBP reviews. Common errors: using a generic HTS code that doesn't match the product's chemical class, listing the country of origin incorrectly, or omitting the FDA product code. Peptides intended for research use should be declared under HTS 2933.99.9300 (other heterocyclic compounds) or 2934.99.2100 (other nucleic acids and their salts), depending on structure. Using HTS 3822.00.0000 (diagnostic or laboratory reagents) is almost always incorrect and triggers secondary review. The FDA product code for peptides not approved as drugs is 54ZR10 (bulk active pharmaceutical ingredient, not for human use). Misusing the code for approved drug products (e.g., 54ZR05) invites immediate referral to FDA's Office of Compliance.
Another recurring issue: the shipper's name on the manifest does not match the name on the COA. CBP now cross-references manufacturer names against FDA's import alert database. If the manufacturer appears on an alert — even for a different product — the entire shipment is held. In Q1 2026, a shipment from a supplier that had received an FDA warning letter in 2023 for misbranding of a different peptide was detained at JFK within 24 hours of arrival, despite the current shipment having a clean COA. The consignee had to provide evidence that the manufacturer had corrected its practices, requiring a site audit report and a corrective action plan — documents most research labs do not have on hand.
What the Pattern Signals for Domestic-Supply Demand
The enforcement pattern is unambiguous: importing research peptides from foreign suppliers has become a high-risk, high-delay proposition. For labs needing consistent supply — especially for longitudinal studies or multi-site collaborations — the seizure rate is now high enough that domestic sourcing is no longer a premium option but a practical necessity. The shift is visible in the growing number of U.S.-based peptide synthesis companies that have invested in ISO 9001:2015 certification and in-house USP <71> and <85> testing. These suppliers can offer per-lot COAs with full compendial testing, eliminating the manifest and identity verification issues that trigger detention.
The regulatory trend line points toward further tightening. FDA's 2025 guidance on "Importation of Active Pharmaceutical Ingredients" explicitly states that peptides imported for research use must still meet the same quality standards as those intended for clinical use, unless the importer holds an active IND. The practical effect: only labs with IND filings — or those sourcing from domestic suppliers with established quality systems — can reliably import without detention. For the majority of research labs, the calculus has shifted: the cost of a domestic peptide, including per-lot COA with endotoxin and sterility testing, is now lower than the cost of a seized shipment plus the administrative burden of responding to an FDA warning letter.
One example of this domestic-supply infrastructure is BAC Water Depot, which publishes per-lot COAs for its bacteriostatic water and peptide reconstitution supplies, contrasting with foreign suppliers that have received warning letters for incomplete documentation. Other domestic peptide suppliers, such as American Peptide Company and CPC Scientific, have similarly invested in ISO 9001:2015 and USP testing. The pattern is clear: the market is consolidating around suppliers that can provide verifiable, compendial-quality documentation at the point of import.
The Bottom Line for Industry Insiders
The 2026 seizure patterns are not random enforcement noise. They reflect a coordinated effort by CBP and FDA to shift the burden of quality verification from the regulator to the importer. The three seizure categories — unlabeled powders, controlled analogs, and COA failures — are predictable and preventable. Labs that continue to import without verifying their supplier's compliance history, COA completeness, and HTS code accuracy will face increasing detention rates and potential inclusion on import alert lists. The domestic supply chain, while smaller, offers a path to reliable, verifiable product that avoids these risks entirely. For research peptide buyers, the question is no longer whether to source domestically, but how quickly they can transition before their next shipment is seized.